Invest in Life
IVAO — reliable partner of investors, scientists, entrepreneurs and experts
in the world of biotechnology, pharmaceuticals and medicine
IVAO News
Get the most relevant news, establish new social connections and communicate with world-known experts.

It’s not an easy environment for health-care investors, with the sector front and center of political debates, but a bigger concern might be stemming from a key regulator: the U.S. Food and Drug Administration.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.

Events and Conferences
Leading Age Leadership Summit USA, Washington
ICT4AWE 2020
North Sea Longevity Conference 2020 Netherlands, Amsterdam
Undoing Aging 2020
Biohacker Summit 2020 Amsterdam Netherlands, Amsterdam
IFA 15th Global Conference on Ageing Canada, Toronto
Database IVAO
The database presents the most promising opportunities for investing your capital.